Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definitions
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates & calculations
1.3.1 Base year calculation
1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
Chapter 2 Executive Summary
2.1 Industry 3600 synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Increasing prevalence of autoimmune disease globally
3.2.1.2 Growing elderly population
3.2.1.3 Increasing consumer awareness
3.2.1.4 Technological advancements in biologic therapies
3.2.2 Industry pitfalls & challenges
3.2.2.1 High cost of the treatment
3.2.2.2 Side effects and adverse reactions
3.3 Growth potential analysis
3.4 Pipeline analysis
3.5 Regulatory landscape
3.6 Porter's analysis
3.7 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company matrix analysis
4.3 Company market share analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Type, 2021 – 2032 ($ Mn)
5.1 Key trends
5.2 IL-1 inhibitors
5.3 IL-2 inhibitors
5.4 IL-5 inhibitors
5.5 IL-6 inhibitors
5.6 IL-17 inhibitors
5.7 IL-23 inhibitors
5.8 Other types
Chapter 6 Market Estimates and Forecast, By Route of Administration, 2021 – 2032 ($ Mn)
6.1 Key trends
6.2 Subcutaneous (SC)
6.3 Intravenous (IV)
Chapter 7 Market Estimates and Forecast, By Application, 2021 – 2032 ($ Mn)
7.1 Key trends
7.2 Rheumatoid arthritis
7.3 Psoriasis
7.4 Inflammatory bowel disease (IBD)
7.5 Asthma
7.6 Other applications
Chapter 8 Market Estimates and Forecast, By End-user, 2021 – 2032 ($ Mn)
8.1 Key trends
8.2 Hospital
8.3 Specialty clinics
8.4 Research and academic institutes
Chapter 9 Market Estimates and Forecast, By Region, 2021 – 2032 ($ Mn)
9.1 Key trends
9.2 North America
9.2.1 U.S.
9.2.2 Canada
9.3 Europe
9.3.1 Germany
9.3.2 UK
9.3.3 France
9.3.4 Spain
9.3.5 Italy
9.3.6 Netherlands
9.3.7 Rest of Europe
9.4 Asia Pacific
9.4.1 Japan
9.4.2 China
9.4.3 India
9.4.4 Australia
9.4.5 South Korea
9.4.6 Rest of Asia Pacific
9.5 Latin America
9.5.1 Brazil
9.5.2 Mexico
9.5.3 Rest of Latin America
9.6 Middle East and Africa
9.6.1 Saudi Arabia
9.6.2 South Africa
9.6.3 UAE
9.6.4 Rest of Middle East and Africa
Chapter 10 Company Profiles
10.1 Abbvie Inc.
10.2 Biogen Inc.
10.3 Eli Lilly and Company
10.4 F. Hoffmann-La Roche Ltd.
10.5 Fujifilm Kyowa Kirin Biologics Co., Ltd.
10.6 Genentech USA, Inc.
10.7 Janssen Pharmaceutical Companies (Johnson and Johnson)
10.8 Novartis AG
10.9 Regeneron Pharmaceuticals, Inc.
10.10 Samsungbioepis Co,.Ltd.
10.11 Sanofi
10.12 Sobi, Inc.
10.13 Sun Pharmaceutical Industries Ltd.
10.14 Teva Pharmaceuticals Industries Ltd.
10.15 UCB S.A
